Tuesday, Sep 24, 2019 8:00a -
Thursday, Sep 26, 2019 5:00p
Revere Hotel Boston Common
200 Stuart Street
Boston, MA 02116
$Conference Only: USD 2599.0, Conference + 2 Workshops: USD 3599.0
Lectures & Conferences
Protect Implanted Cells from a Patients’ Alloimmunity and Autoimmunity to Create a Curative Cell Therapy for Diabetes
Despite decades of research, diabetes remains a public health challenge of epidemic proportions. The underlying goal in research and therapy has been the restoration of insulin function and normoglycemia.
The Cell Therapies for Diabetes Summit is focused on optimizing the clinical and commercial development of these cell therapies with improved manufacturing and streamlined logistical strategies to develop curative therapy to improve the lives of millions of patients worldwide.
Bringing together the pioneers of cell therapies for diabetes we will discuss how to develop assays and biomarkers in order to enhance cell characterization to predict clinical translation, and ultimately improve efficacy, providing patients with life-changing therapies.
Discuss the membrane microstructure for encapsulation devices to protect implanted cells from a patient’s alloimmunity and autoimmunity. Join us, and leading experts from Novo Nordisk, Nestle, Sanofi, Kadimastem, ViaCyte and Beta O2 as we drive progress towards the future of diabetes care.
Speakers: Amir Lichter,CEO, Beta O2 Technologies, Yanick Fanton, Lab Director, Beta-Cell NV, Lorenzo Piemonti, Director of Diabetes Research Institute and Human Islet Transplantation Program, IRCCS Ospedale San Raffaele, Marjana Marinac, Director, Regulatory Affairs for Drugs and Biologics, JDRF, Albert Hwa, Operations Director, CCTD, Joslin Research Center, Kfir Molakandov, Head of Diabetes Research, Kadimastem, Marine Kraus, Team Leader, Stem Cells, Nestle Institute of Health Sciences, Mathias Svahn, CEO, Next Cell Pharma, Matthias von Herrath, Vice President and Senior Medical Officer, Type 1 Diabetes and Stem Cells, Novo Nordisk, Kenneth Waggoner, CEO, President and General Counsel, PharmaCyte Biotech, Jason Fontenot, Senior Vice President, Cell Therapy, Sangamo Therapeutics, Krister Bokvist, Head of Islet Biology, Sanofi, Bjarki Johannesson, Senior Investigator, The New York Stem Cell Foundation, Maike Sander, Director of the Pediatric Diabetes Research Center, UC San Diego, Per-Ola Carlsson, Professor of Medical Cell Biology, Uppsala University, Jay Skyler, Professor, University of Miami, Eugene Brandon, Senior Director of Strategic Relations, ViaCyte, Jeffrey Millman, Assistant Professor, Medicine and Biomedical Engineering, Washington University St Louis